True Wealth Design’s Cytek Biosciences CTKB Stock Holding History

True Wealth Design’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.52K	Sell	569 -142	-20%	-$606	﹤0.01%	1593
2026 Q1	$3.11K	Buy	711 +98	+16%	+$463	﹤0.01%	1386
2025 Q4	$3.1K	Sell	613 -204	-25%	-$947	﹤0.01%	1282
2025 Q3	$2.83K	Sell	817 -32	-4%	-$120	﹤0.01%	1338
2025 Q2	$2.89K	Sell	849 -314	-27%	-$1.05K	﹤0.01%	1020
2025 Q1	$4.66K	Buy	+1,163	New	+$6.03K	﹤0.01%	709

Other funds holding CTKB

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $5.7B AUM 35.76% 1-Year Est. Return

NAM

NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

True Wealth Design's CTKB Position: Q2 2026 in Review

True Wealth Design reduced its Cytek Biosciences (CTKB) stake by 20% in Q2 2026, selling an estimated $606 and leaving 569 shares worth $2.52K. The position accounts for ﹤0.01% of the portfolio, ranked #1593.

True Wealth Design first reported a position in CTKB in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.66K in Q1 2025. 14 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

True Wealth Design held 569 shares of Cytek Biosciences worth $2.52K as of Q2 2026.
True Wealth Design sold 142 Cytek Biosciences shares in Q2 2026, an estimated $606.
Cytek Biosciences made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #1593 holding.
True Wealth Design first reported a position in Cytek Biosciences in Q1 2025 and has held it in 6 quarters since.
True Wealth Design's Cytek Biosciences position peaked at $4.66K in Q1 2025.
14 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.